Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

SpectraCure

0,17 SEK

-2,91 %

Mindre end 1K følgere

SPEC

First North Stockholm

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
-2,91 %
-14,45 %
-0,95 %
-61,16 %
-84,57 %
-67,76 %
-94,37 %
-97,83 %
-73,24 %

SpectraCure operates in the medical technology sector. The company specializes in research and development of medical technology systems used for the treatment of prostate cancer. The cancer treatments are based on proprietary systems that emit laser light sources and photoreactive drugs, a treatment methodology used for internal solid tumors of various types. The largest operations are found in the Nordic market. The company has its headquarters in Lund.

Læs mere
Markedsværdi
68,41 mio. SEK
Aktieomsætning
76,44 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
19.2
2026

Årsrapport '25

27.5
2026

Delårsrapport Q1'26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse23.2.2024, 08.30

SpectraCure takes the next step in the work with the new clinical study

SpectraCure
Pressemeddelelse23.1.2024, 10.45

A well-accomplished annual audit in accordance with ISO 13485:2016

SpectraCure
Selskabsmeddelelse19.12.2023, 07.30

Expert group comments on results of ongoing study

SpectraCure

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse16.11.2023, 14.30

SpectraCure has decided to seek approval for a clinical study of primary prostate cancer

SpectraCure
Pressemeddelelse6.10.2023, 12.30

SpectraCure strengthens presence among urologists

SpectraCure
Selskabsmeddelelse27.6.2023, 09.30

SpectraCure has been awarded an additional EU grant for industrialisation of the company's treatment system Q-PRO®

SpectraCure
Selskabsmeddelelse7.12.2022, 10.00

SpectraCures signs Letter of Intent with Cheplapharm

SpectraCure
Selskabsmeddelelse30.8.2022, 09.00

SpectraCure: Patent regarding the new generation of treatment systems approved in Europe

SpectraCure
Selskabsmeddelelse7.6.2022, 12.15

SpectraCure has been approved a grant from EU of € 125,000

SpectraCure
Pressemeddelelse16.5.2022, 09.00

A new Board has been installed at SpectraCure

SpectraCure
Selskabsmeddelelse15.4.2021, 12.00

The Nomination Committee's proposal for election of board members in SpectraCure AB

SpectraCure
Selskabsmeddelelse5.3.2021, 09.30

SpectraCure: Status update regarding clinical studies for the treatment of patients with recurrent prostate cancer

SpectraCure
Selskabsmeddelelse16.9.2020, 14.48

SpectraCure: Looking for excellent, highly-skilled education and training in the vibrant field of Biophotonics? Apply now!

SpectraCure
Selskabsmeddelelse26.6.2020, 14.30

SpectraCure raises approximately SEK 140 million through a fully subscribed rights issue

SpectraCure
Selskabsmeddelelse7.4.2020, 11.00

Patent application enters PCT phase, SpectraCure ensures development and work

SpectraCure
Selskabsmeddelelse12.3.2020, 12.35

The meeting between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA takes place tomorrow, March 13 2020

SpectraCure
Selskabsmeddelelse17.1.2020, 15.50

A welcome addition to support our ongoing product development. SpectraCure receives research contribution from the EU.

SpectraCure
Selskabsmeddelelse26.11.2019, 16.56

SpectraCure: Last day of trading of SPEC TO3 subscription warrants tomorrow, Nov. 27

SpectraCure
Selskabsmeddelelse13.11.2019, 15.20

SpectraCure's main owner subscribes in full for his share

SpectraCure
Selskabsmeddelelse12.11.2019, 15.00

SpectraCure AB Quarterly Report (1 July to 30 September) 2019

SpectraCure
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.